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Abstract
The structural and functional integrity of the retinal pigment epithelium (RPE) is fundamental for maintaining the function of the neuroretina.
These specialized cells form a polarized monolayer that acts as the retinal–blood barrier, separating two distinct environments with highly
specialized functions: photoreceptors of the neuroretina at the apical side and Bruch’s membrane/highly vascularized choriocapillaris at the
basal side. The polarized nature of the RPE is essential for the health of these two regions, not only in nutrient and waste transport but also in
the synthesis and directional secretion of proteins required in maintaining retinal homoeostasis and function. Although multiple malfunctions
within the RPE cells have been associated with development of age-related macular degeneration (AMD), the leading cause of legal blindness,
clear causative processes have not yet been conclusively characterized at the molecular and cellular level. This article focuses on the involve-
ment of directionally secreted RPE proteins in normal functioning of the retina and on the potential association of incorrect RPE protein
secretion with development of AMD. Understanding the importance of RPE polarity and the correct secretion of essential structural and
regulatory components emerge as critical factors for the development of novel therapeutic strategies targeting AMD.
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Introduction
The RPE consists of a monolayer of cells that form the retinal–blood
barrier (RBB). On either side of this cellular monolayer lie two con-
trasting environments that are critical for the correct functioning of
the neuroretina. Immediately on the apical side of the RPE is a thin
matrix known as the interphotoreceptor matrix (IPM) [1, 2]. Embed-
ded in this matrix are the highly specialized photoreceptor cells. On
the basal side of the RPE lies another unique cellular support
structure, the Bruch’s membrane (an elastogenesis product of the
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RPE/choroid) as well as the fenestrated epithelium of the choriocapil-
laris. The role the RPE plays in separating neural and vascular tissues
is similar to that of the blood–brain barrier (BBB); the RBB, however,
is unique in that the RPE acts as the impermeable barrier to nutrient/
waste movement, as opposed to the endothelial cells in the vessel
walls, as is the case for the BBB [3].
One of the main functions of the RPE is in the delivery of nutrients
from the choroid to the photoreceptor cells, whilst transporting meta-
bolic end products, ions and excess water in the opposite direction
[4–6]. This function alone renders RPE a critical role in maintaining
the retinal homoeostasis. However, the RPE also carries out other
essential functions in visual cycle, phagocytosis of spent photorecep-
tor outer segments [7, 8], light absorption [7], and the expression
and secretion of retinal proteins [9]. Failure of the RPE to conduct
any of these processes efficiently can lead to retinal degeneration,
and bring about diseases such as AMD – the leading cause of legal
blindness in the Western world [10]. Although multiple malfunctions
within the specialized cells in the retina, most importantly in the sup-
portive RPE, have been associated with development of this disease
of multifactorial origin, clear causative processes have not yet been
conclusively established.
Maintenance of the structure and function of the microenviron-
ments on either side of the RPE via protein secretion is the focus of
this article, with specific emphasis on the importance of directional,
targeted secretion of trophic/growth factors and structural/structure-
related proteins.
RPE polarity
The RPE displays many similarities to other epithelial layers, including
a hexagonal ‘cobblestone’ appearance, organization as a single mono-
layer, tight junctions between cells and a highly polarized nature. Mor-
phologically, RPE cells display polarity with apical microvilli, pigment
granules and well-developed tight junctions located on the apical side
of the cell, as well as basally located nuclei and membrane infolding
[11, 12] (Fig. 1). A feature that distinguishes RPE from other epithelia
is the fact that its apical surface does not face an acellular lumen.
Instead, it is immediately adjacent to a layer of highly specialized
cells, the photoreceptors.
Proteins expressed by RPE cells can also be localized to either api-
cal or basal plasma membrane (PM) (Fig. 1), such as the apical cell
membrane protein NaK-ATPase [11–13], and the basally located anion
channel, bestrophin [14]. The localization of such proteins can also
distinguish RPE cells from other epithelia, as for example, NaK-AT-
Pase is localized to the basal membrane in other epithelial cells [15].
The polarized organization of the RPE is crucial for its interaction
with both its apical and basal side, as well as in the directionality of its
protein secretion. It has been demonstrated that attainment of polarity
in vitro increases the overall levels of growth factor secretion [16].
Mechanisms by which cell polarization occur and is maintained, as
well as the consequences of altered polarity and trafficking in disease
states have been reviewed elsewhere [17]. In the case of RPE, it is also
therefore likely that factors altering the polarity of the monolayer may
play an important role in the development of diseases such as AMD.
Retinal pigment epithelium cells secrete a host of growth factors
and structural/structure-related proteins [9] (Table 1), and there is no
doubting the importance of such secretion in supporting photorecep-
tor survival, as well as in maintenance of the retinal blood supply.
However, the importance of directional protein secretion can often be
overlooked, despite the fact it has been demonstrated that many pro-
teins are secreted preferentially by either the apical, or basolateral PM.
Some examples of directional protein secretion from the RPE are
discussed below. The function/dysfunction of the majority of proteins
presented herein have direct links to AMD pathogenesis. For those
that have not, to date, been directly linked with AMD, we hypothesize
how their incorrect localization/function may lead to retinal degenera-
tion based on their involvement in fundamental biological processes
and on similarities of their mechanism of action with that of known
molecular determinants of the disease.
Apical secretion from the RPE
Matrix metalloproteinase 2 (MMP-2) and tissue
inhibitor of matrix metalloproteinase 1 (TIMP-1)
Matrix metalloproteinase and TIMPs are apically secreted by the RPE
[43]. MMPs play a crucial role in the extracellular matrix (ECM) turn-
Fig. 1 The highly polarized retinal pigment epithelium (RPE) at the inter-
face between the retina and choroid. The organization of cellular struc-
tures into apical and basolateral domains is highlighted. At the apical
surface, the microvilli of the RPE closely interact with the photoreceptor
outer segments. On the basal side, the RPE are supported by the
Bruch’s membrane, beneath which lies the choroidal blood supply. This
highly polarized arrangement ensures that the RPE remains a selectively
permeable barrier between these two contrasting tissues.
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Table 1 Proteins secreted by the RPE and their putative functions in relation to AMD
Protein Main function/s Links/potential links to AMD Polarity# References
aB Crystallin Molecular chaperone,
cytoprotection
Possible AMD biomarker, maybe involved in Drusen
formation
Apical [18–20]
BDNF Neurotrophic growth factor Protective role for the photoreceptors possibly lost
during AMD
Unknown [21,22]
CFH Inhibitor of the complement
pathway
Gene variants implicated as a major AMD risk factor Unknown [23]
CNTF Neurotrophic growth factor May provide protection against neurodegenerative
diseases, such as AMD
Unknown [21,24]
Cystatin C Cysteine protease inhibitor Variant B isoform associated with increased risk of
“wet” AMD
Basal [25,26]
Endothelin I Vasoconstriction/vasodilation Mis-signalling associated with retinopathies associated
with breakdown of blood–retinal barrier
Basal [27]
*Fibulin 3/5 ECM protein involved in
elastogenesis (fibulin 5)
Variant isoform of fibulin 5 associated with increased
risk of AMD
Unknown [28,29]
FGF 2 Growth factor involved in
mitogenesis, angiogenesis
and cell survival
Role in choroidal neovascularization Unknown [21,30,31]
FGF 5 Growth factor involved in
mitogenesis, angiogenesis
and cell survival
Potential functional role in AMD pathophysiology Basal [32,33]
HB-EGF Mitogenic growth factor Indirect role in choroidal neovascularization via influence
on VEGF expression
Unknown [21,34]
HGF Growth factor involved in
growth, motility and
morphogenesis
Provides protection to RPE cells under oxidative stress,
a process frequently linked with AMD progression
Unknown [21,35]
Hyaluronan Major component of ECM Possible role in choroidal neovascularization via
interaction with CD44 receptor
Apical [36,37]
IGF-I Growth factor involved in
growth and development
Role in choroidal neovascularization Unknown [38,39]
LIF Cytokine involved in
differentiation
May aid photoreceptor survival during periods of stress,
such as AMD
Unknown [21,40]
MMP-2 Zinc-dependent endopeptidase
involved in ECM degradation
Activity within the Bruch’s membrane altered in AMD,
possible contribution to progression of “wet” AMD
Apical [41–43]
MMP-9 Zinc-dependent endopeptidase
involved in ECM degradation
Activity within the Bruch’s membrane altered in AMD,
possible contribution to progression of “wet” AMD
Unknown [41,42]
NGF Neurotrophic growth factor Provides protection to RPE cells under oxidative stress,
a process frequently linked with AMD progression
Unknown [21,44]
PEDF Growth factor with neurotrophic
and anti-angiogenic properties
Incorrect expression/localization promotes vascularization,
loss of photoreceptor support role in late-stage AMD
Apical [11,12,45,46]
TGF-b Growth factor involved in
proliferation and
differentiation
Can cause senescence-associated changes in RPE,
a process associated with early AMD
Apical [24,47,48]
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over throughout the body. Their activity is normally tightly regulated
at several levels, including functional inhibition by TIMPs. It has been
suggested that apically secreted MMPs/TIMPs could play a crucial
role in the turnover and structural maintenance of the IPM, or
possibly be involved in degrading the tips of photoreceptor outer
segments, signalling their readiness for phagocytosis by the RPE
[43].
Matrix metalloproteinase and TIMPs (including MMP-2 and TIMP-
1) are also present basally to the RPE, in the Bruch’s membrane
[51–53]. This indicates potential basolateral secretion of MMPs
[54,55]. It is possible that the RPE is able to secrete certain MMPs/
TIMPs in opposite directions depending on external cues such as
cytokine stimulation [55], or signals from the ECM [43]. Alternatively,
MMPs/TIMPs present in Bruch’s membrane could be secreted by
choroidal cells. MMP activity is disturbed in the Bruch’s membrane in
AMD [42], and the MMPs role in angiogenesis [56] could also con-
tribute to symptoms associated with the ‘wet’ (exudative) form of the
disease. Malfunctions in controlled, directional secretion of MMPs/
TIMPs could disrupt the balance of proteolytic activity on either side
of the RPE, contributing to age-related changes in the IPM and
Bruch’s membrane.
Hyaluronan
Hyaluronan is a widely distributed glycosaminoglycan, and is a major
component of the ECM. It is secreted from the apical side of the RPE
[37], where it is believed to function as the primary scaffold protein in
the IPM [1]. Maintaining the structural integrity of the IPM is a crucial
function of the RPE, and mis-localization of hyaluronan could lead to
its degeneration, subsequently affecting the survival of the light
sensitive cells of the outer retina. Indeed, it has been demonstrated
that the IPM is abnormally distributed in an animal model for retinal
degeneration [57]. The interaction of hyaluronan with the receptor
CD44 has been associated with choroidal neovascularization, a
common symptom of wet AMD [36]. Such an interaction could be
the result of mis-targeting of the protein to the wrong tissue
compartment.
aB crystallin
aB crystallin is a molecular chaperone induced by stress stimuli. By
suppressing protein aggregation and inhibiting the proteolytic activity
of caspase 3, it is able to play a role in cytoprotection [58]. aB Crys-
tallin is secreted from the apical surface of the RPE, where it is taken
up by the photoreceptor cells. Here, it inhibits the activity of caspase
3, activates the DNA repair and apoptosis-related Poly (ADP-ribose)
Polymerase (PARP) and provides the photoreceptors with protection
from oxidative stress [20]. More recent data suggest that the protein
is released from the cell inside exosomes, and that its secretion is
independent of the endoplasmic reticulum (ER)/Golgi/secretory path-
way [19]. aB crystallin is a major component of the IPM [59, 60] and
has also been linked to AMD pathogenesis, with increased expression
being proposed as a possible biomarker for the disease [18]. Under
severe oxidative stress, the RPE barrier can become compromised,
resulting in aB crystallin aggregating on the basal side of the RPE
[20]. In this case, not only is the protein less available to provide a
survival advantage to the photoreceptors but it can also contribute to
the formation of drusen deposits [18].
Pigment epithelium-derived factor (PEDF)
The PEDF is highly expressed in the retina, where it serves as a neu-
rotrophic factor [61] and angiogenesis inhibitor [45]. Multiple stud-
ies have shown that PEDF is secreted preferentially from the apical
surface of the RPE [11, 12, 46], where it provides such neurotrophic
support to the photoreceptors, and maintains a non-angiogenic
retinal environment [16]. Low levels of PEDF below the basal surface
of the RPE may aid in preventing vascularization in this compart-
ment as well. Dysregulated expression of both PEDF and vascular
endothelial growth factor (VEGF) (discussed below) plays a role in
the pathogenesis of late-stage AMD [45]. A delicate balance exists
on either side of the RPE regarding the concentrations of these
two growth factors. Disrupting this balance can promote vasculari-
zation of the retina, whilst simultaneously decreasing photoreceptor
support [16].
Table 1. Continued
Protein Main function/s Links/potential links to AMD Polarity# References
TIMP-I Inhibitor of matrix
metalloproteinases
Activity of target molecules (MMP’s) altered in AMD,
possible contribution to progression of “wet” AMD
Apical [41–43]
Tropoelastin Involved in formation of elastin
fibres (such as in Bruch’s
membrane)
Potential functional role in AMD-related changes
in the Bruch’s membrane
Unknown [49]
VEGF Angiogenic growth factor Incorrect expression/localization promotes
vascularization role in late-stage AMD
Basal [12,50]
#Putative polarity of secretion is indicated based on experimental data published to date.
*Fibulin 3 (EFEMP 1) is known to be secreted from RPE cells [28], but its function and possible role in AMD development have not been fully
characterized. The closely related Fibulin 5 is associated with AMD development and although secretion from RPE cells has not been demon-
strated experimentally, it is actively secreted by other cell lines [29].
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Basolateral secretion from the RPE
Fibroblast growth factor 5 (FGF-5)
Fibroblast growth factor 5 is known to play a role in a range of
processes including angiogenesis [62, 63], cell survival [64] and
mitogenesis [65, 66]. It is secreted basally from the RPE and has a
possible paracrine role in choroid function, or alternatively, acts as an
autocrine survival factor for RPE cells [32]. Whatever its precise func-
tion in the retina, it is conceivable that its mis-regulated secretion
could have detrimental effects on RPE cell survival, or vascularization,
and therefore it has been suggested that it plays a role in the patho-
physiology of AMD [33].
Endothelin I
Endothelin I is a protein expressed in the retina and choroid [67]. It
acts on two receptors located in smooth muscle cells, resulting in
both vasoconstriction and vasodilation [68]. It is secreted from the
basal surface of the RPE, and by interacting with its receptors in the
choriocapillaris, can regulate blood flow [27]. It has been proposed
that stresses involved in the breakdown of the blood–retinal barrier,
as in AMD, can cause an increase in the expression and secretion of
endothelin I, suggesting a role in wound repair via effects on prolifer-
ation and cell migration [27].
Vascular endothelial growth factor
Vascular endothelial growth factor is a pro-angiogenic growth factor
that is secreted preferentially from the basal surface of the RPE [12,
50]. VEGF modulates and maintains the extracellular space in and
around the Bruch’s membrane, and modulates the growth/density of
endothelial cells in the choriocapillaris [69–71]. Its secretion is
normally tightly regulated, thus preventing its concentration levels
from surpassing a critical threshold able to induce vascularization
[16]. However, considering its potent angiogenic properties, it is
plausible that the incorrect localization of this growth factor can be a
critical factor in late-stage exudative AMD. This theory is supported
by findings that elevated local concentration of VEGF can result in the
formation of abnormal blood vessels, as seen in AMD [72].
Cystatin C
Cystatin C is a reversible inhibitor of cysteine proteinases including
papain and cathepsins B, H, L and S [73, 74]. A polymorphism pres-
ent in the genomic sequence of the cystatin C gene produces a
mutant variant of the protein referred to as variant B. Homozygosity
for this variant has been shown to correlate with an increased risk
of developing exudative AMD, with a relatively early onset [26]. It is
likely that cystatin C is secreted from the basolateral side of the
RPE [25] and the AMD-related variant has been shown to present a
significantly reduced secretion. When considering this protein’s
function, its link to AMD, and the fact that the activity of its main
group of substrates, the cathepsins, is altered in AMD [75–77], it is
conceivable that its directional secretion could be highly important
in the maintenance and turnover of the Bruch’s membrane and
choriocapillaris.
Mechanisms of protein secretion/
polarized secretion
A large number of soluble proteins are secreted from the PM via the
relatively well-characterized ‘classical’ secretion pathway. These
proteins contain N-terminally located signal peptides, directing them
co-translationally to the translocation apparatus of the ER [78].
Following vesicular transport from the ER to the Golgi apparatus,
secreted proteins are then packaged into Golgi-derived vesicles that
ultimately fuse with the PM, releasing their contents into the extracel-
lular space [79–82]. Alternatively, many proteins are also secreted
from the cell via other, ‘non-classical’ mechanisms. These proteins
typically lack a signal peptide, and are excluded from organelles that
are essential during ‘classical’ secretion, such as the ER and Golgi.
These mechanisms of secretion are reviewed in detail elsewhere [83],
and include import into endosomal sub-compartments, direct translo-
cation across the PM, and membrane blebbing, releasing the secreted
proteins via exosomes.
In polarized cells, secretion requires an extra level of complexity
and control to ensure certain proteins are targeted to, and released
from the appropriate cell surface. Mechanisms required for such con-
trol have been studied extensively within the ‘classical’ secretion path-
way, and have been reviewed in detail elsewhere [84–86]. Although
the majority of this work has focused on the targeting of membrane-
bound proteins, many secreted proteins are likely targeted via similar
mechanisms. Thus, the basolateral versus apical sorting mechanisms
in the secretory pathway is believed to rely on complex membrane
trafficking pathways which also underpin the distinct specialization of
the apical and basolateral PM domains. Targeting of proteins to a
particular cell surface takes place at the level of the trans-Golgi
network (TGN), following incorporation of apical and basolateral
proteins into distinct vesicles [87–90], a process that usually requires
the presence of directional sorting signals. More recently, it has been
suggested that some targeting may actually occur earlier than the
TGN [91]. In addition, the endocytosis pathway itself is regulated to
preserve the polarity of lipid and protein components following inter-
nalization and recycling. Some of the potential mechanisms required
for directional protein secretion are discussed below and summarized
in Figure 2.
Basolateral sorting signals
Basolateral sorting signals typically consist of tyrosine-based (YxxØ,
FxNPxY) or di-leucine-based peptide sequences, found in the dis-
posed, cytoplasmic portion of transmembrane proteins [84, 89, 91].
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Interestingly, these basolateral signals are usually dominant over their
apical counterparts [92]. In many cases, these signal peptides are
recognized, and directly bind to heterotetrameric clathrin adapter pro-
tein complexes. This event triggers the incorporation of cargo into
nascent vesicles, which are subsequently trafficked to the basolateral
PM [84, 93]. As these adaptor proteins are thought to mediate trans-
port between the TGN and endosomal compartments, it is possible
that some basolateral proteins traverse recycling endosomes before
reaching the PM [91]. Indeed, the importance of indirect sorting of
proteins via such endosomal pathways has been highlighted [94–96].
Alternatively, some proteins are targeted directly to the PM [97].
Although there are only few examples of basolateral signals demon-
strated in secreted proteins, it is likely that these are sorted in a
similar fashion as transmembrane proteins.
A B
C D
Fig. 2Models for targeted protein secretion from the endoplasmic reticulum (ER)-Golgi secretory pathway. Proteins containing apical sorting signals
(A in white circle), basolateral sorting signals (B in red square) or no sorting signals (plain white rectangle) are delivered from the ER in ER derived
vesicles (ERDV). Upon entering the Golgi apparatus, proteins progress to the trans-Golgi network (TGN) and sorting occurs. In pathway (A), apical
signals (glycans, GPI linkages) interact with specific cellular machinery (e.g. apical targeting receptors, lipid rafts), resulting in packaging into apical
vesicles (1). These vesicles can then traffic directly to the apical plasma membrane (PM) for extracellular release (2). Alternatively, some proteins
are first trafficked to endosomes (E) (3), or to the basolateral PM (4). Basally trafficked proteins are subsequently redirected to the apical PM via
transcytosis, either directly, or via endosomes (5). Proteins in the endosomal pathway are subsequently trafficked to the apical PM (6). In pathway
(B), proteins that lack a typical targeting signal can undergo ‘specialized packaging’ in particular environments (yellow area). For example, proteins
with an affinity for lipids can localize in areas of high lipid content. These proteins are subsequently packaged into vesicles and targeted to the apical
PM directly (1, 2), or indirectly via endosomes (1, 3, 4). In pathway (C), basolateral signals interact with a specific cellular machinery (e.g. clathrin
adapters), resulting in packaging into basolateral vesicles (1). It is possible that some secreted proteins are packaged into secretory vesicles (2) dis-
tinct from those used for transmembrane proteins (circular vesicle versus rectangular). Basolateral vesicles can then traffic to the basolateral PM
directly (3), or via endosomes (4, 5). For some secreted proteins (e.g. TGFa), the cytoplasmic domain is cleaved, resulting in secretion of the
mature form (6). Pathway (D), can act as a default for any proteins not otherwise targeted (proteins that lack a typical targeting signal), or alterna-
tively, proteins that do not enter pathway (B) (e.g. due to lack of affinity for lipids). These proteins are subsequently packaged into vesicles and tar-
geted to the basolateral PM directly (1, 2), or indirectly via endosomes (1, 3, 4).
838 ª 2013 The Authors.
Journal of Cellular and Molecular Medicine Published by Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Transforming growth factor-a (TGFa) provides one of the
relatively few examples of a typical basolateral signal in a secreted
protein. Its precursor form (pro-TGFa) contains a dominant basolat-
eral sorting signal within the cytoplasmic region that is subsequently
cleaved to produce the soluble, mature form [98]. It has also been
suggested that basolateral secretion can occur independently of any
sorting signal, relying instead on a default, cell-dependent pathway
that is governed by the association of particular proteins to intracellu-
lar lipids [99]. The overall lipid content of the cell, as well as the lipid
composition of apical and basal vesicles are therefore important
factors in this process. There is also evidence of separate
branches within the basolateral sorting pathway for secreted and
transmembrane proteins, resulting in loading into distinct carrier
vesicles [100].
Apical sorting signals
Apical sorting signals are much more diverse than basolateral signals
and consist of post-translational modifications, rather than distinct
peptide sequences. Perhaps the most extensively studied of these are
N- and O-linked glycans, which are present on particular proteins.
Two models have been proposed to explain how these glycans are
involved in apical sorting [101]. The first suggests that these carbo-
hydrates are critical for the assumption of a correct conformation that
is necessary to progress along the biosynthetic pathway. The second
model suggests the existence of a sorting receptor that recognizes
carbohydrates, or alternatively, protein conformations that are depen-
dent upon such carbohydrates. Glycans can also cause aggregation
of proteins into pre-export complexes [91]. Non-glycan apical sorting
signals have also been suggested, imagined as three-dimensional
proteinaceous patches [101]. Glycosylphosphatidylinositol (GPI) link-
ages enable sorting through association with apical PM-bound lipid
rafts [92]. Apical sorting can also occur independently of signals
(glycosylation). In this case, it is hypothesized that certain cell types
can provide an environment that encourages ‘specialized packaging’
of proteins destined for apical secretion [102].
The route that apical proteins take to the PM seems as equally
diverse as the signals that direct them. Many transmembrane proteins
destined for the apical PM are transported from the TGN in different
vesicles, and are then processed via distinct subsets of endosomal
compartments before reaching their final destination [103, 104]. It is,
however, hypothesized that soluble, secreted proteins may in fact be
targeted directly to the PM, to avoid degradation within the endocytic
pathway [86]. RPE cells, in particular, also differ in their processing
of many apical proteins, directing them first to the basolateral PM,
before a process of relocation to the apical PM via transcytosis [105].
Mechanisms for targeting secreted proteins for apical PM release
are similar to those for transmembrane proteins. Glycans can pro-
mote such targeting, as is the case during apical sorting of rat growth
hormone [106]. Glycoprotein 2 is targeted to the apical PM via a GPI
anchor in its transmembrane domain. Subsequent cleavage then
results in secretion of the soluble form [107] in a similar manner to
the basolateral secretion of TGFa. Human growth hormone, thyro-
globulin and parathyroid hormone have been shown to be secreted
apically, independently of known apical signals, relying instead on
particular cellular conditions [102].
Consequences of impaired RPE protein secretion
It is becoming increasingly apparent that directional protein secretion
is a highly regulated and complex process, and that malfunctions
occurring at any step in these pathways could lead either to
increased/decreased levels of essential growth factors and structural
proteins in the extracellular space or to their incorrect intracellular/
extracellular localization. It is therefore possible that such malfunc-
tions could serve as relatively overlooked mechanisms in the patho-
physiology of the highly secretory RPE, with specific consequences
for the development of retinal disorders such as AMD.
Indeed, such alterations in protein secretion have been implicated
in the development of other diseases. Such an example is the
increase in growth factor secretion from cancer cells, leading to auto-
crine growth stimulation and metastasis [108]. Secretion of cystatin
C variant B from human primary fibroblasts has also been shown to
be reduced compared with the wild-type [109]. It is possible that such
reduced secretion of cystatin C in the brain can result in a lack of pro-
tection following toxic insult, or in stem-cell mediated regeneration,
factors that may contribute to the development of Alzheimer’s disease
[109]. A recent study has demonstrated that cells derived from
patients with AMD display a striking difference in the secretion of sev-
eral proteins compared with matched healthy donors. Many of these
proteins are involved in angiogenesis and protein aggregation, pro-
cesses that have been heavily implicated in AMD pathogenesis [110].
Extracellular mislocalization of secreted proteins can occur as a
result of changed cell polarity and alterations in directional secretion.
Such alterations can also have implications in disease development.
The presence of the Alzheimer’s-linked, ‘Swedish’ double mutation in
the amyloid precursor protein results in a proportion being mis-
secreted from the apical, rather than basolateral PM [111]. Directional
secretion can also be altered as a result of external stimulation of cells
with cytokines [112, 113], the activity of which can be altered in dis-
ease states. Total secretion of important factors such as PEDF (api-
cally or basally) from RPE cells can be dependent on the cell attaining
a highly polarized configuration [16, 114], again highlighting the
importance of polarity for correct protein secretion.
Some of the RPE-secreted proteins highlighted above have been
shown to have altered secretion patterns during AMD development.
MMP-2 is secreted at levels threefold higher in AMD RPE cells com-
pared with healthy RPE [110]. It is possible that this protease is indi-
rectly involved in angiogenesis via its proteolytic and ECM
remodelling properties [115]. PEDF secretion is also, surprisingly,
increased in AMD RPE cells [110]. It has been suggested that this
may be a compensatory response by the RPE to balance the angio-
genic properties of VEGF [110]. This same study [110] was also able
to show an increase in clusterin secretion and a decrease in SPARC
secretion in AMD cells. The precise function of clusterin has not been
defined, but its presence in Drusen suggests that it may be involved
in their formation [116, 117], therefore contributing to one of the
greatest hallmarks of AMD. SPARC is known to have anti-angiogenic
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properties [118, 119], meaning reduced levels in the choroid could
aid in neovascularization.
One of the most abundantly expressed and secreted proteins of
the RPE is the cysteine proteinase inhibitor cystatin C [120]. The role
that this protein plays in the RPE has not yet been characterized, yet
its function as a cysteine proteinase inhibitor together with its extra-
cellular targeting [25] suggest an important involvement in matrix
remodelling and turnover, processes that are essential for retinal ho-
moeostasis. A signal peptide present in the 26 amino acid leader
sequence [121] of cystatin C targets it to the ‘classical’ ER/Golgi
secretory pathway [25]. The polymorphism that results in the variant
B cystatin C translates into an amino acid substitution (alanine to
threonine) at the penultimate position of this leader sequence. This
alteration results in a failure of cystatin C to efficiently enter the secre-
tory pathway, leading to a diffuse intracellular distribution of the
protein, an association with mitochondria, and a reduction in its
secretion of ca. 50% [122, 123]. Reduced hydrophobicity of the sig-
nal sequence caused by the amino acid substitution is thought to be
the cause of this secretory malfunction [124].
Concluding remarks
The tissues on either side of the RPE present two different microenvi-
ronments, each placing varying demands on the RPE in terms of
protein requirements. High levels of particular growth factors and
structural proteins that can be beneficial in one compartment can be
detrimental in the other. Maintaining the correct concentrations of
particular factors, in the correct location, at the correct time is there-
fore of critical importance for retinal health.
This article highlights several examples of directional protein
secretion by the RPE, all of which could play important roles in
maintaining its surrounding extracellular environments. Malfunctions
in trafficking/secretory pathways can lead to mis-localization of these
proteins, which can ultimately manifest as a number of AMD
symptoms.
Therapies such as RPE transplants and gene therapy could offer
improved treatments for AMD in the future. The importance of polar-
ity and directional protein secretion in maintaining RPE/retinal func-
tioning will be key considerations in the further development of such
therapies.
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